Eli Lilly is positioned as a key beneficiary of AI in drug discovery, using its scale and research capabilities to speed up new molecule development and expand its product portfolio. Despite a high forward price-to-earnings ratio of 40, the company is rated a Buy for the next 2-3 years due to expected strong earnings growth and investor enthusiasm. While long-term AI adoption across the industry may pressure margins and valuations, the near-term outlook remains positive, making dips attractive buying opportunities.
Eli Lilly shares are currently up 2.46% on Pluang, trading at USD 1,444.00 with a market cap of $1.26 trillion. As of Nov 04, 2026 20:11 WIB, the platform shows a balanced investor interest with 59% buying activity and a typical hold time of 94 days.
Eli Lilly reported a 39% increase in revenue driven by a 53% rise in volume, despite a 15% decline in realized prices. The company's gross margin improved to 83.9%, reflecting strong operational efficiency. Most revenue comes from the obesity drug ti...
Eli Lilly reported a robust third quarter with revenue up 38.6% to $24.4 billion, driven by a 53% increase in tirzepatide volume. CEO David Ricks emphasized growth beyond weight-loss drugs, highlighting advances in immunology, oncology, and neuroscie...
The AI-driven bull market faces challenges as investors rotate from high-spending tech stocks like Nvidia to traditionally defensive stocks such as Walmart and Eli Lilly. Despite strong earnings in some tech sectors, the Nasdaq-100 and semiconductor ...
Eli Lilly reported strong recent financial results with solid revenue growth and robust margins, even raising its guidance. However, signs of slowing revenue growth in the near future could impact margins and temper enthusiasm. Despite this, Eli Lill...
Eli Lilly, having reached a $1.146 trillion market cap largely due to weight-loss drugs Mounjaro and Zepbound, is now showing strong growth potential in oncology, immunology, and neuroscience sectors, with Q2 revenue from these areas up 121% year ove...
